• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
158075 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  * V, K/ _1 G% d8 h  L
$ a$ W* N' }3 g  @6 M: e" I
5 C1 h/ b3 @/ ?/ s
Sub-category:
9 k* |+ o0 G" M" n& {" {2 B: i# n% KMolecular Targets & C& k1 @' z8 a" v9 V

1 Y/ G! [$ V! q5 k
: T& C* b5 [- F& RCategory:
9 T. `! O; m' PTumor Biology
8 |2 y  c9 C1 B) ~5 n
9 t4 z& }2 K+ w0 Q" T+ x- O% _1 J! ^2 k
Meeting:: h: ~, ?* n9 Q3 e
2011 ASCO Annual Meeting , b9 r7 K$ v( N3 t- y6 d+ g

" H3 F$ S, F! z8 n5 m0 R4 o
3 c% M' I. F0 ~, G. q3 QSession Type and Session Title:2 S) v/ `( g+ e1 O+ {: h
Poster Discussion Session, Tumor Biology
2 m0 o0 U" [2 V* j0 j* n; D" o. u1 Q) l( b
9 Z; Y; D9 I" E3 q: S+ }' e
Abstract No:$ Q  i- Z1 ]7 Z9 E" ]0 p4 o! u* Y
10517 0 H- R+ P% r2 d! v. l# o! d7 D

4 R9 j, {. c% X2 a- H3 i( h$ t9 S, v! M0 o8 X7 @& k
Citation:
) i8 i# c4 ~4 TJ Clin Oncol 29: 2011 (suppl; abstr 10517) , t0 S  D+ q- a& M+ J. S
; y8 W9 F: t+ J' m+ Z

$ X$ c, c8 P9 n' f7 l/ @+ r2 J$ V& oAuthor(s):
' s, b+ d: B3 a) kJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China + K8 d; ^1 W9 b. P! o

6 \3 F' O9 q  W- E2 ~$ Q
7 @: M0 b% U: r, v& B6 R
1 h& F" U2 j! ^% ]$ vAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.4 m$ y0 J* G1 ~* R) Q+ Y- s6 O& h* b
5 t2 p) }, \, l+ N0 S2 f7 H
Abstract Disclosures; h- H+ D& g  ^* I  i/ ^

5 D7 n' U" v; f3 ~4 vAbstract:
- z  w: V7 X  i) \' X9 ]$ W. X# F$ u' i- B& r
* k+ o& J' g7 s% T/ B
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.7 N5 M6 e$ ^+ p' G2 m
! [5 G5 c9 H4 ^5 K8 u* X/ Y' J

1 P: |. i+ F# n
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
( n1 |1 z8 A) Q' h1 S. U没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
0 [/ [, _- C& f( M5 u$ E! G
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ! Q2 E# w: s# G; Y8 @( a) Y
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
' k. M8 v) t! @  a+ ^ALK一个指标医院要900多 ...
9 x; y. a* o6 z1 C& I& j
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?2 d3 k* x0 J/ C$ j$ e; K6 }6 o- B
- Z6 ~1 f. w8 c) c5 g& L7 ~7 u
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表